Advanced search
Publication Cover
Current Medical Research and Opinion Volume 23, 2007 - Issue 10
Submit an article Journal homepage
110
Views
14
CrossRef citations to date
0
Altmetric
Review

Reviewing CATIE for clinicians:balancing benefit and risk using evidence-based medicine tools

Jamie Karagianis Eli Lilly Canada Inc., Toronto, Ontario, Canada; Memorial University of Newfoundland, St. John's, Newfoundland, CanadaCorrespondence[email protected]
,
Michael Rosenbluth Toronto East General Hospital, Toronto, Ontario, Canada
,
Mauricio Tohen Lilly Research Laboratories, Indianapolis, IN, USA; McLean Hospital, Harvard Medical School, Belmont, MA, USA
,
Haya Ascher-Svanum Lilly Research Laboratories, Indianapolis, IN, USA; Indiana University School of Medicine, Indianapolis, IN, USA
,
Tamas Treuer Eli Lilly and Company, Vienna, Austria
,
Mauricio Silva de Lima Eli Lilly and Company, São Paulo, Brazil; Federal University of Pelotas, Pelotas, Brazil
&
Leslie Citrome New York University School of Medicine, New York, NY, USA; Nathan S Kline Institute for Psychiatric Research, Orangeburg, NY, USA
 show all
Pages 2551-2557 | Accepted 16 Aug 2007, Published online: 07 Sep 2007

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Justin Faden, Natasha Kiryankova-Dalseth, Ruby Barghini & Leslie Citrome. (2021) Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?. Expert Opinion on Pharmacotherapy 22:5, pages 635-646.
Read now
William Montgomery, Tamas Treuer, Jamie Karagianis, Haya Ascher-Svanum & Gavan Harrison. (2012) Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties. Patient Preference and Adherence 6, pages 109-125.
Read now
Srihari Gopal, Joris Berwaerts, Isaac Nuamah, Kasem Akhras, Danielle Coppola, Ella Daly, David Hough & Joseph Palumbo. (2011) Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. Neuropsychiatric Disease and Treatment 7, pages 93-101.
Read now
. (2011) Erratum. Current Medical Research and Opinion 27:4, pages 835-836.
Read now
Joshua T Kantrowitz & Leslie Citrome. (2008) Olanzapine: review of safety 2008. Expert Opinion on Drug Safety 7:6, pages 761-769.
Read now
Leslie Citrome & Joshua Kantrowitz. (2008) Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Review of Neurotherapeutics 8:7, pages 1079-1091.
Read now

Articles from other publishers (8)

Ross J. BaldessariniRoss J. Baldessarini. 2013. Chemotherapy in Psychiatry. Chemotherapy in Psychiatry 31 88 .
Renrong Wu, David E. Kemp, Martha Sajatovic, Jingping Zhao, Joseph R. Calabrese & Keming Gao. (2011) Communication of Potential Benefits and Harm to Patients and Payers in Psychiatry: A Review and Commentary. Clinical Therapeutics 33:12, pages B62-B76.
Crossref
T. A. Ketter, L. Citrome, P. W. Wang, J. L. Culver & S. Srivastava. (2011) Treatments for bipolar disorder: can number needed to treat/harm help inform clinical decisions?. Acta Psychiatrica Scandinavica 123:3, pages 175-189.
Crossref
B Levitan. (2010) A Concise Display of Multiple End Points for Benefit–Risk Assessment. Clinical Pharmacology & Therapeutics 89:1, pages 56-59.
Crossref
Babu Rankupalli & Rajiv Tandon. (2010) Practicing evidence-based psychiatry: 1. Applying a study's findings: The threats to validity approach. Asian Journal of Psychiatry 3:1, pages 35-40.
Crossref
Mauricio Tohen, Jennifer Sniadecki, Virginia K. Sutton, Elisabeth K. Degenhardt, Jamie L. Karagianis, Doron Sagman & Jennie G. Jacobson. (2009) Number Needed to Treat or Harm Analyses of Olanzapine for Maintenance Treatment of Bipolar Disorder. Journal of Clinical Psychopharmacology 29:6, pages 520-528.
Crossref
Virginia Stauffer, Jamie Karagianis, Virginia Sutton, Haya Ascher-Svanum, Tamas Treuer, Mauricio de Lima, Tamara Ball, Vicki Poole-Hoffmann & Mauricio Tohen. (2008) Number Needed to Treat (NNT) and Number Needed to Harm (NNH) in Randomized, Blinded Trials Comparing Olanzapine to Other Atypical Antipsychotics for Treatment of Schizophrenia. Clinical Schizophrenia & Related Psychoses 2:2, pages 136-146.
Crossref
L. Citrome. (2008) Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatrica Scandinavica 117:6, pages 412-419.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.